TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17177907

Group type: EXPERIMENTAL
Intervention: Wives who used religious coping along with their husbands (group 3)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Wives who used religious coping while their husbands did not (group 2)
Number of subjects: 101
Study: 14676664

Group type: EXPERIMENTAL
Intervention: Suprapubic catheter drain after bladder repair
Number of subjects: 42

Group type: COMPARATOR
Intervention: Urethral catheter alone
Number of subjects: 42
Study: 12768736

Group type: EXPERIMENTAL
Intervention: HBO combined with medical treatment (treatment group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: HBO only (control group)
Number of subjects: 60
Study: 8972649

Group type: EXPERIMENTAL
Intervention: MR angiography
Number of subjects: 50

Group type: COMPARATOR
Intervention: Spin-echo MR imaging
Number of subjects: 50
Study: 1292233

Group type: EXPERIMENTAL
Intervention: Obsidane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sydnopharm
Number of subjects: 0
Study: 6366151

Group type: EXPERIMENTAL
Intervention: Erythrocyte sedimentation rate (ESR)
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Presence or absence of systemic symptoms
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Combination of ESR and systemic symptoms
Number of subjects: 676
Study: 30667317

Group type: EXPERIMENTAL
Intervention: DE iMAR Mono+
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DE iMAR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DE Mono+
Number of subjects: 20

Group type: COMPARATOR
Intervention: Original DE mixed images
Number of subjects: 20
Study: 30441954

Group type: EXPERIMENTAL
Intervention: faUUT
Number of subjects: 838

Group type: COMPARATOR
Intervention: inUUT
Number of subjects: 838
Study: 27128667

Group type: EXPERIMENTAL
Intervention: Loaded breathing (six breaths per min, 18 cm H2O)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Unloaded breathing (six breaths per min, no load)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (normal breathing)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Loaded breathing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Unloaded breathing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Loaded breathing and Unloaded breathing
Number of subjects: 30
Study: 25327394

Group type: EXPERIMENTAL
Intervention: Oligofructose (8 g/d for ages 7-11 years and 15 g/d for ages 12-18 years) for 12 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (maltodextrin) for 12 weeks
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Oligofructose
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 22037844

Group type: EXPERIMENTAL
Intervention: Medical interventions
Number of subjects: 157

Group type: COMPARATOR
Intervention: Non-medical interventions
Number of subjects: 157
Study: 20467874

Group type: EXPERIMENTAL
Intervention: Strength training program for 10 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acute strength training session
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (physically inactive)
Number of subjects: 15
Study: 18020845

Group type: EXPERIMENTAL
Intervention: Computer-assisted intervention
Number of subjects: 866

Group type: COMPARATOR
Intervention: Computer-based control condition
Number of subjects: 866
Study: 16817786

Group type: EXPERIMENTAL
Intervention: Half-dose of nafamostat mesilate (NM)
Number of subjects: 4

Group type: COMPARATOR
Intervention: No nafamostat mesilate (NM)
Number of subjects: 4
Study: 12798518

Group type: EXPERIMENTAL
Intervention: Standard two-dose Yuzpe (levonorgestrel-ethinyl estradiol)
Number of subjects: 1682

Group type: EXPERIMENTAL
Intervention: Norethindrone-ethinyl estradiol
Number of subjects: 1682

Group type: EXPERIMENTAL
Intervention: Single dose of Yuzpe (levonorgestrel-ethinyl estradiol)
Number of subjects: 1682

Group type: COMPARATOR
Intervention: Single dose of Yuzpe
Number of subjects: 1682

Group type: EXPERIMENTAL
Intervention: Standard two-dose Yuzpe, Norethindrone-ethinyl estradiol, Single dose of Yuzpe
Number of subjects: 1682
Study: 10973451

Group type: EXPERIMENTAL
Intervention: MnCC vaccine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Quadrivalent polysaccharide vaccine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Unimmunized control group
Number of subjects: 45
Study: 8774029

Group type: EXPERIMENTAL
Intervention: Good Readers
Number of subjects: 108

Group type: COMPARATOR
Intervention: Poor Readers
Number of subjects: 108
Study: 1611441

Group type: EXPERIMENTAL
Intervention: Whole blood transfusion
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Filtered blood transfusion
Number of subjects: 197

Group type: COMPARATOR
Intervention: No blood transfusion
Number of subjects: 197
Study: 6318185

Group type: EXPERIMENTAL
Intervention: Early immunization (DTP in the newborn nursery)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Routine immunization (DTP at 2, 4, and 6 months)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control infants with high cord IgG anti‐LPT titers
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Early immunization group with lower cord IgG anti‐LPT titers
Number of subjects: 35
Study: 30906944

Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Whey protein supplement
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: In-home rehabilitation + placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: In-home rehabilitation + whey protein
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Active intervention groups (combined)
Number of subjects: 100
Study: 29031778

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg orally once a day for 6 years
Number of subjects: 1860

Group type: COMPARATOR
Intervention: Anastrozole 1 mg orally once a day for 3 years
Number of subjects: 1860
Study: 26156156

Group type: EXPERIMENTAL
Intervention: FOLFOX-4
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: FOLFOX-4 + Cetuximab
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control arm (colectomy and adjuvant chemotherapy)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (FOLFOX-4) for RAS mutated patients
Number of subjects: 165
Study: 23041003

Group type: EXPERIMENTAL
Intervention: NCEP-ATP III definition of MetS
Number of subjects: 5198

Group type: EXPERIMENTAL
Intervention: AHA/NHLBI definition of MetS
Number of subjects: 5198

Group type: EXPERIMENTAL
Intervention: IDF definition of MetS
Number of subjects: 5198

Group type: EXPERIMENTAL
Intervention: JIS definition of MetS
Number of subjects: 5198

Group type: EXPERIMENTAL
Intervention: All definitions of MetS
Number of subjects: 5198
Study: 21217408

Group type: EXPERIMENTAL
Intervention: Customized free-form PAL spectacles
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard non-free-form PAL spectacles
Number of subjects: 95
Study: 18511470

Group type: EXPERIMENTAL
Intervention: 0.9 mg rhTSH
Number of subjects: 24
Study: 16970138

Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin every other day
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo tablet every other day
Number of subjects: 39876

Group type: EXPERIMENTAL
Intervention: 600 IU of vitamin E on intervening days
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo capsule on intervening days
Number of subjects: 39876
Study: 15004251

Group type: EXPERIMENTAL
Intervention: Amlodipine (calcium-channel blocker)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Valsartan (AT1-receptor blocker)
Number of subjects: 77

Group type: COMPARATOR
Intervention: L-NMMA (NO synthase inhibitor)
Number of subjects: 77
Study: 11075941

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg twice daily for 5 days
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg once or twice daily for 7 days
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 9126182

Group type: EXPERIMENTAL
Intervention: Probing attachment level change over one year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probing attachment level change over two years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-year change in probing attachment level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-year change in probing attachment level
Number of subjects: 0
Study: 1555688

Group type: EXPERIMENTAL
Intervention: Standard hormone replacement therapy (HRT) regimen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Standard HRT regimen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Reduced doses of estradiol valerate (1/3 of standard)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Reduced doses of progesterone (1/5 of standard)
Number of subjects: 18
Study: 3930255

Group type: EXPERIMENTAL
Intervention: 500 mg dose of UDCA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 250, 500, or 750 mg doses of UDCA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: UDCA (various doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Higher doses of UDCA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repeated daily doses of UDCA
Number of subjects: 12
Study: 30737555

Group type: EXPERIMENTAL
Intervention: Capsaicin (12 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (isocaloric)
Number of subjects: 13
Study: 30485351

Group type: EXPERIMENTAL
Intervention: Accessible video for students with visual impairments
Number of subjects: 228

Group type: COMPARATOR
Intervention: Non-accessible video
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Accessible video
Number of subjects: 228
Study: 27039236

Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol (BUD/FM) 320/9 μg via pressurized metered-dose inhaler (pMDI)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 320 μg via pMDI
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Formoterol (FM) 9 μg via dry-powder inhaler
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study: 24562799

Group type: EXPERIMENTAL
Intervention: Plasma levels of MAp44 in MI patients (18% higher than control group, p<0.001)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Plasma levels of MASP-1 in MI patients (elevated, p=0.002)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Plasma levels of MASP-3 in MI patients (elevated, p<0.001)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Healthy control group plasma levels of MAp44, MASP-1, and MASP-3
Number of subjects: 192
Study: 22854910

Group type: EXPERIMENTAL
Intervention: Ambulation training intervention
Number of subjects: 108
Study: 20106824

Group type: EXPERIMENTAL
Intervention: Combined ramipril at 5 mg/day, valsartan at 80 mg/day and increased furosemide dosage
Number of subjects: 18

Group type: COMPARATOR
Intervention: Combined ramipril at 5 mg/day and valsartan at 80 mg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Combined ramipril at 10 mg/day and valsartan at 160 mg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diuretic dosage uptitration
Number of subjects: 18
Study: 17394248

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of selected CD133(+) and CD133(−) CD34(+) progenitor cells
Number of subjects: 24

Group type: COMPARATOR
Intervention: Medical therapy (Control)
Number of subjects: 24
Study: 16359280

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12068300

Group type: EXPERIMENTAL
Intervention: Professional musicians
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non‐musicians
Number of subjects: 37
Study: 10215718

Group type: EXPERIMENTAL
Intervention: Urine colour (scored on an eight-point scale)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subjective assessment of urine colour by intensive care nurses
Number of subjects: 40
Study: 8583437

Group type: EXPERIMENTAL
Intervention: Danazol 200 mg daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2243411

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter monitoring
Number of subjects: 102

Group type: COMPARATOR
Intervention: Central venous catheter monitoring
Number of subjects: 102
Study: 28480

Group type: EXPERIMENTAL
Intervention: novel pyridylbenzodiazepine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 31195307

Group type: EXPERIMENTAL
Intervention: Fiberoptic evaluation of nasal cavity, pharynx and larynx
Number of subjects: 129
Study: 29211699

Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy (RG)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Laparoscopic gastrectomy (LG)
Number of subjects: 163
Study: 26282658

Group type: EXPERIMENTAL
Intervention: Olaparib (100 mg twice per day) plus Paclitaxel (80 mg/m² on days 1, 8, and 15 of every 28-day cycle)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo plus Paclitaxel (80 mg/m² on days 1, 8, and 15 of every 28-day cycle)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Olaparib (200 mg twice per day) as maintenance therapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo as maintenance therapy
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Olaparib/paclitaxel in ATMlow population
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo/paclitaxel in ATMlow population
Number of subjects: 124
Study: 25103522

Group type: EXPERIMENTAL
Intervention: Interesterified palm olein (IPO)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Native palm olein (NPO)
Number of subjects: 11
Study: 22074414

Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring the impact of bipolar disorder
Number of subjects: 21
Study: 19416224

Group type: EXPERIMENTAL
Intervention: Relaxin 3 microg/kg of body weight/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxin 10 microg/kg of body weight/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxin 30 microg/kg of body weight/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17582923

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (4.5 g to 9 g a day)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (at least 6 g a day)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (continuing treatment)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 690
Study: 15693087

Group type: EXPERIMENTAL
Intervention: Vitamins C and E (500 mg vitamin C and 800 IU vitamin E daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 11923638

Group type: COMPARATOR
Intervention: P792 (0.0065, 0.013, 0.026, and 0.039 mmol/kg)
Number of subjects: 32
Study: 9785922

Group type: EXPERIMENTAL
Intervention: Laparoscopic linear salpingostomy (group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single-dose methotrexate (group 2)
Number of subjects: 30
Study: 7665720

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day (Lo group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (P1 group)
Number of subjects: 34
Study: 2652569

Group type: EXPERIMENTAL
Intervention: OKT3 (5 mg intravenous bolus)
Number of subjects: 88

Group type: COMPARATOR
Intervention: MAG (20 mg/kg/day)
Number of subjects: 88
Study: 963865

Group type: EXPERIMENTAL
Intervention: Intranasal betamethasone valerate aerosol for 28 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral antihistamine compound
Number of subjects: 30
Study: 30773551

Group type: EXPERIMENTAL
Intervention: Feldspathic porcelain (Noritake®) by slurry molding
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lithium disilicate glass ceramic (IPS E.max® Press) by heat‐pressed
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Feldspar porcelain block (VITA Mark II®) by CAD/CAM
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zirconia‐reinforced glass ceramic (VITA Suprinity®) by CAD/CAM
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hybrid ceramic with a ceramic‐polymer network (VITA Enamic®) by CAD/CAM
Number of subjects: 30
Study: 28778464

Group type: COMPARATOR
Intervention: GET 73 single ascending doses (10, 30, 100, 300, 450, 600 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: GET 73 multiple ascending doses (100, 300, 450 mg twice a day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: GET 73 (single and repeated doses)
Number of subjects: 80
Study: 25494871

Group type: EXPERIMENTAL
Intervention: Fasting (48-hour duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise (3 intensities)
Number of subjects: 0
Study: 24292304

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (3 doses of 250mg/kg per dose, 24 hours apart)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline infusion (3 doses, 24 hours apart)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 50
Study: 21440036

Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 3009

Group type: COMPARATOR
Intervention: TIV
Number of subjects: 3009
Study: 19624440

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN) self-administered vaginally at home
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo self-administered vaginally at home
Number of subjects: 350
Study: 16711497

Group type: EXPERIMENTAL
Intervention: Continuous posterior tibial nerve block with 0.375% ropivacaine (5 mL x h(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral analgesia (metamizole 575 mg/6 h p.o.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups received 50 mg/8 h p.o. of tramadol as rescue analgesia
Number of subjects: 40
Study: 15181066

Group type: EXPERIMENTAL
Intervention: 1000 mg TU i.m.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (4 ml castor oil i.m.)
Number of subjects: 28
Study: 14630678

Group type: EXPERIMENTAL
Intervention: Oral capecitabine 1250 mg/m² twice daily, days 1-14 every 21 days
Number of subjects: 1967

Group type: COMPARATOR
Intervention: i.v. bolus 5-FU 425 mg/m² with i.v. leucovorin 20 mg/m² on days 1-5, repeated every 28 days
Number of subjects: 1967
Study: 10468217

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol 2 g/d combined with L-ascorbic acid 3 g/d for 50 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 7572007

Group type: EXPERIMENTAL
Intervention: dopexamine (2 micrograms.kg‐1 min‐1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 2144260

Group type: EXPERIMENTAL
Intervention: UK 79300 (25 or 50 mg p.o.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7350036

Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid (CCDA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bilron (750 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control periods
Number of subjects: 8
Study: 31696369

Group type: EXPERIMENTAL
Intervention: Adapted active visualization intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 28
Study: 28860012

Group type: EXPERIMENTAL
Intervention: Continuous administration of rocuronium (continuous-NMB-group)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Bolus administration of rocuronium (bolus-NMB-group)
Number of subjects: 63
Study: 25370322

Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Number of subjects: 122

Group type: COMPARATOR
Intervention: Insulin Aspart
Number of subjects: 122
Study: 24306705

Group type: EXPERIMENTAL
Intervention: Trochanteric flip osteotomy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Standard posterior approach
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Modified posterior approach
Number of subjects: 50
Study: 21293136

Group type: EXPERIMENTAL
Intervention: Nissen's fundoplication
Number of subjects: 64

Group type: COMPARATOR
Intervention: Dor fundoplication
Number of subjects: 64
Study: 18705632

Group type: EXPERIMENTAL
Intervention: Azelaic acid 20% cream
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metronidazole 0.75% cream
Number of subjects: 24

Group type: COMPARATOR
Intervention: Permethrin 5% cream
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All topical creams
Number of subjects: 24
Study: 17096661

Group type: EXPERIMENTAL
Intervention: Wavelet Dynamic Discrimination algorithm (Medtronic, Minneapolis, MN, USA) with a match threshold of 70%, operating in ON mode.
Number of subjects: 1122
Study: 15480125

Group type: EXPERIMENTAL
Intervention: Health policy research initiatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current research initiatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Policy development
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study methodology
Number of subjects: 0
Study: 11709782

Group type: EXPERIMENTAL
Intervention: Heterozygous CCR5 Delta32
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: SDF-1 homozygous 3'A variant
Number of subjects: 354

Group type: COMPARATOR
Intervention: Wild type (+) and variant genotypes
Number of subjects: 354
Study: 9536541

Group type: COMPARATOR
Intervention: Topical lithium succinate ointment (Efalith), applied twice daily.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 0
Study: 8195977

Group type: EXPERIMENTAL
Intervention: Tc‐99m‐MDP (20 mCi) injection and gamma-camera scanning
Number of subjects: 26

Group type: COMPARATOR
Intervention: Blade and screw type implants using the non‐submerged, one‐stage technique
Number of subjects: 26
Study: 29101865

Group type: EXPERIMENTAL
Intervention: Co-parenting breastfeeding support intervention including in-hospital discussion, breastfeeding booklet, co-parenting workbook, website, DVD, supportive emails, and proactive telephone call.
Number of subjects: 214
Study: 27464900

Group type: EXPERIMENTAL
Intervention: Locally Adapted Personal Protective Equipment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Daily Practice Clothing
Number of subjects: 45
Study: 24002929

Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (low dose): 0.125 mg/kg/min (1 min) loading followed by 0.02 mg/kg/min (20 min) continuous infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (high dose): 0.25 mg/kg/min (1 min) loading followed by 0.04 mg/kg/min (20 min) continuous infusion
Number of subjects: 20